Coronary balloon angioplasty, stents, and scaffolds
Since the first coronary angioplasty on Sept 16, 1977, the field of percutaneous coronary
intervention has evolved rapidly. Now marking its 40th anniversary, percutaneous coronary …
intervention has evolved rapidly. Now marking its 40th anniversary, percutaneous coronary …
Restenosis, stent thrombosis, and bleeding complications: navigating between Scylla and Charybdis
The field of interventional cardiology has significantly evolved over 40 years by overcoming
several challenges. The introduction of first-generation drug-eluting stents significantly …
several challenges. The introduction of first-generation drug-eluting stents significantly …
Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data …
D Giacoppo, F Alfonso, B Xu… - European Heart …, 2020 - academic.oup.com
Aims Consensus is lacking regarding the best treatment for coronary in-stent restenosis
(ISR). The two most effective treatments are angioplasty with paclitaxel-coated balloon …
(ISR). The two most effective treatments are angioplasty with paclitaxel-coated balloon …
[HTML][HTML] Acute coronary syndromes in diabetic patients, outcome, revascularization, and antithrombotic therapy
Diabetes exacerbates the progression of atherosclerosis and is associated with increased
risk of developing acute coronary syndrome (ACS). Approximatively 25–30% of patients …
risk of developing acute coronary syndrome (ACS). Approximatively 25–30% of patients …
Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary …
Background Drug-eluting stents combining an ultrathin cobalt-chromium stent platform with
a biodegradable polymer eluting sirolimus have been shown to be non-inferior or superior to …
a biodegradable polymer eluting sirolimus have been shown to be non-inferior or superior to …
Drug-eluting stent thrombosis: current and future perspectives
S Kuramitsu, S Sonoda, K Ando, H Otake… - Cardiovascular …, 2021 - Springer
Over the past 40 years, the safety and efficacy of percutaneous coronary intervention has
dramatically improved by overcoming several challenges. The introduction of drug-eluting …
dramatically improved by overcoming several challenges. The introduction of drug-eluting …
Bioresorbable vascular scaffolds for coronary revascularization
Contemporary metallic drug-eluting stents are associated with very good 1-year outcomes
but an ongoing risk of stent-related adverse events (thrombosis, myocardial infarction …
but an ongoing risk of stent-related adverse events (thrombosis, myocardial infarction …
Intravascular ultrasound versus angiography-guided drug-eluting stent implantation: a health economic analysis
Background: There is increasing evidence that use of intravascular ultrasound (IVUS)
guidance during percutaneous coronary intervention (PCI) is associated with improved …
guidance during percutaneous coronary intervention (PCI) is associated with improved …
[HTML][HTML] Magmaris: a new generation metallic sirolimus-eluting fully bioresorbable scaffold: present status and future perspectives
C Rapetto, M Leoncini - Journal of thoracic disease, 2017 - ncbi.nlm.nih.gov
Drug-eluting stents (DES) have reached a high safety and efficacy profile, becoming the best
option for percutaneous coronary interventions (PCI) based revascularization. However …
option for percutaneous coronary interventions (PCI) based revascularization. However …
The evolution of coronary stents
P McKavanagh, G Zawadowski, N Ahmed… - Expert Review of …, 2018 - Taylor & Francis
Introduction: Percutaneous coronary intervention (PCI) is 40 years old this year. From its
humble beginnings of experimental work, PCI has transitioned over years with coronary …
humble beginnings of experimental work, PCI has transitioned over years with coronary …